Clinical Research Directory
Browse clinical research sites, groups, and studies.
AZA Combined with R-GemOx for Elderly DLBCL Patients
Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Summary
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of AZA（azacytidine）combined with the R-GemOx (rituximab, gemcitabine and oxaliplatin) regimen as first-line treatment in elderly diffuse large B-cell lymphoma (DLBCL) patients.
Official title: AZA Combined with R-GemOx for the Initial Treatment of Elderly DLBCL: an Open, Single-arm, Multicenter Clinical Study
Key Details
Gender
All
Age Range
60 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-02-01
Completion Date
2028-01-01
Last Updated
2025-01-16
Healthy Volunteers
No
Conditions
Interventions
azacytidine
Azacytidine: 75mg/m2, d1-d5
R-GemOx
Rituximab: 375mg/m2, d6; Gemcitabine: 1g/m2, d7 Oxaliplatin: 100mg/m2, d7
Locations (1)
Daping Hospital, Third Military Medical University (Army Medical University)
Chongqing, China